Visualization of Sweat Suppression Following Botulinum Toxin A by Soluble Microneedle Arrays

The document reports on a study that investigated the use of botulinum toxin A (BTA) delivered through proprietary soluble microneedle arrays, known as Flex-PADS, for the treatment of hyperhidrosis (excessive sweating). The study conducted split-body tests on mouse footpads, comparing the sweat suppression efficacy of BTA-loaded Flex-PADs to traditional intradermal injections. The results, measured by a modified starch/iodine assay, showed that the Flex-PADs led to similar levels of sweat inhibition as the injections. This novel delivery method also has potential applications for treating painful skin conditions like pachyonychia congenita (PC) and epidermolysis bullosa simplex (EBS), which are responsive to BTA but typically require heavy anesthesia or sedation. The findings suggest that Flex-PADs could offer a patient-friendly alternative for delivering BTA in clinical settings.